cyrilzakka/clinical-trials huggingface dataset:
Intimate Partner Violence and Pregnancy, a Perinatal Care Intervention Study

The study composes of two large parts, in particular a large scale prevalence/incidence study and a single-blind randomised controlled trial (RCT). The prevalence/incidence study aims to determine the prevalence/incidence of physical, psychological and sexual violence in a pregnant population. The study population is recruited through the prenatal consultation of more or less 15 hospitals in Belgium. The respondents fill out a questionnaire on the spot minimum one time during pregnancy. Based on this questionnaire, the investigators aim to recruit 150 victims of intimate partner violence (IPV) to participate in the second part of the study. The RCT aims to evaluate if there is a safe and effective way to reduce IPV within the perinatal care setting. The investigators hypothesise that screening pregnant women for violence in combination with handing out a resource card, has the potential of interrupting the IPV and increase help-seeking behaviour.


Eligibility Criteria:
Inclusion Criteria:

* Dutch-, French- or English speaking
* Victim of intimate partner violence based on the questionnaire
* Accessible through telephone and no safety problems

Exclusion Criteria:

* Not Dutch-, French- or English speaking
* Not a victim of intimate partner violence one year before or during pregnancy
* Not accessible through telephone and/or safety problems
Use of a Reinforced Injectable Calcium Phosphate Bone Cement in the Treatment of Tibial Plateau Fractures

Case series of tibial plateau fractures using Norian Drillable.

This study is a multi-center, non-randomized prospective case series of tibial plateau fractures using Norian Drillable to fill bone voids, to evaluate OR time, blood loss, complications, ease of use, fracture stabilization and patient function and pain over time.

Eligibility Criteria:
Inclusion Criteria:

* Subjects with closed tibial plateau fractures classified as OTA B2, B3 or C3 resulting in a bone void.
* At least 18 years of age.
* Psychosocially, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms.
* Signed informed consent.

Exclusion Criteria:

* Critically ill
* Mentally ill or mentally disordered
* Wards of the state
* Prisoners
* Refugees
* In an employer - employee, teacher - student relationship or any other dependant with the researchers or their associates
* Active or suspected infection - systemic or local
* Gustillo classification of 2 or 3
* Bilateral tibial plateau fractures when both fracture patterns extend into the joint
* Have an existing calcium metabolism disorder (e.g. hypercalcemia)
* Chronic renal disease/renal failure
* Insulin dependent diabetes
* Taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids).
* Rheumatoid arthritis or other autoimmune disease.
* Systemic disease including AIDS, HIV, hepatitis.
* Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years.
* Subjects involved in other studies within the last month, prior to screening.
* Pregnant or interested in becoming pregnant in the next 18 months. Females of child-bearing potential must use an acceptable method of contraception during trial participation.
The Montreal Neighbourhood Networks and Healthy Aging Panel

Social networks, social capital, i.e., network-accessed resources, and neighbourhood environments have been shown associated with a range of health behaviours and conditions, including obesity, physical activity, nutrition, and mental health. Research on social capital and health in Montreal has shown the importance of network social capital for a person's subjective health status, sense of control, self-reported physical activity, and obesity. Research has also shown high social capital to reduce health service use, mental health service use, and improve the management of chronic illnesses. Despite advances in the understanding of social capital and its link to health and health service use, most research on social capital is cross sectional and is unable to identify the causal pathways linking social networks and capital to health and health care use. Longitudinal research would strengthen the evidence base for designing interventions to prevent or delay the use of health services, particularly in older adults.

This research has three main objectives: (1) transform the original sample of Montreal Neighbourhood Networks and Healthy Aging (MoNNET-HA) households (n=2707) into a panel study, (2) link the MoNNET-HA participant data to their Quebec Health Insurance Registry (Régie de l'assurance maladie (RAMQ)) information, and (3) assess the feasibility of extending the MoNNET-HA panel by one wave to include participant's core network members. Unique about the original MoNNET-HA sample is that it purposefully oversampled older adults (\> 64 years old) but remains representative of Montreal adults at various ages and income levels. In addition, MoNNET-HA data is integrated into a GIS database which allows researchers to examine the effects of neighbourhood environmental characteristics on health. By linking MoNNET-HA data to RAMQ, researchers will be able to examine patterns of diagnosed health conditions, (e.g., fractures, depression), pharmaceutical use and adherence, and formal health care use over time. Transforming the cross-sectional study into a panel study would also allow researchers to examine longitudinally the dynamics of health and health care utilization among Panel participants over the life course, and the causal pathways linking neighbourhoods and networks to health and health care use.


Eligibility Criteria:
Inclusion Criteria:

* Adults 25 years and older,
* Residents of the Montreal Metropolitan Area, Canada,
* Had to reside at current residence for at least one year

Exclusion Criteria:

* Non- French or English-speaking households
* Institutionalized
The Effect of Injectable PRF Vs LLL on Orthodontic Tooth Movement

The purpose of the present study is to compare the effect of injectable platelet fibrin and Low Level LASER therapy on the rate of upper canine retraction, and on root resorption of the canine

the study involves two groups the first group received low level laser at the upper right canine, while the upper left canine act as a control. The second group received injectable platelet rich fibrin at the upper right canine, while the upper left canine act as a control. in each group we will compare rate of canine retraction between both sides, and amount of root resorption also we will compare both groups regarding rate of canine retraction and amount of root resorption

Eligibility Criteria:
Inclusion Criteria:

1. Patients with age 18 years or older.
2. Presence of all permanent teeth except for the third molar.
3. Presence of malocclusion requiring maxillary first premolar extraction such as (class II division 1 or bimaxillary dentoalveolar protrusion).

Exclusion Criteria:

1. Patient with a history of previous orthodontic treatment.
2. Medical problems may interfere with orthodontic treatment.
3. Bad oral hygiene.
Active Control of Prostatic Cancer With Criteria of Latence

This study concern a prospective cohort pf patients with latent prostate cancer. We study the specific survival at 10 years of patients who accept an active control.Patients inclusion are realized in 2 stages:

* patient with inclusion criteria (PSA \< 10 ng/ml, clinical stage T1c or T2a, Gleason \< or = 6) are registered if they accept a second prostate biopsy in a 3 months delay
* after analyse of second biopsy in central laboratory and confirmation of latent prostate biopsy, patients are included if they accept active control Included patients will have 1 biopsy by years the first two years and then 1 biopsy each 2 years during 8 years.

If progression of cancer happens during the 10 years control, active control will be stopped and patient will be treated by surgery and chemotherapy.

This study concern the active control during 10 years of patient with latent prostate cancer who accept not be treated immediately.

Eligibility Criteria:
Inclusion Criteria:

* patient with a latent prostatic cancer
* aged less 75 years old,
* life expectation higher than 10 years
* Clinic statue T1c or T2a
* with a seric PSA (prostatic specific antigen)smaller than 10ng/ml
* more than 10 biopsy cores samples
* patient with less than 3 cores samples with tumor and none care sample with more than 3mm of tumor
* Gleason score inferior at 7
* patient's agreement about project and a second biopsy which will include definitive patient: realized 3 months after the first and having: 14 biopsy cores samples (10 like previously and 4 more specific: taking around the positives initials biopsies), less than 3 cores samples with tumor, ,any cores samples with more than 3mm of tumor, a Gleason score superior at 7.

Exclusion Criteria:

* patient aged 75 years old and more
* no patient's agreement
* lack of understanding of plan
* patient with guardianship
* life expectation smaller than 10 years
* patient with an other cancer less than 5 years
* Local clinical statue greater than T2a
* seric PSA higher than 10ng/ml
* less than 10 biopsies
* more than 2 positives biopsies during the first intervention
* 3 cores samples with more than 3mm of tumor
* 4th grade on the biopsies
* patient's refuse to realize the second biopsies
* patient who ask a treatment after the first medical examination
* patient with less 4 special biopsies around the previously initial cores samples or more than 2 positives biopsies or biopsies with more than 3mm of tumor or patient having a 4 grade on biopsies, during the second medical examination.
PhosphoRus, Proton Imaging and Amyloid BuRdEn (PREPARE) ON AMYLOID BURDEN AND COGNITION

Normal cells primarily produce energy with the help of the "mitochondria". These "small organs" are also called the "powerhouses of the cell" turn the sugars, fats and proteins that is eaten into forms of chemical energy that the body can use to carry on living. This process is called oxidative phosphorylation. In addition to the help from the mitochondria and oxidative phosphorylation, most cells can produce energy by lactic acid fermentation. This process is less energy efficient but faster and used by the brain, muscle or other organs under specific circumstances and energy demands, even in the presence of abundant oxygen. It is also called aerobic glycolysis. Aerobic glycolysis and oxidative phosphorylation are the two major mechanisms involved in brain energetics.

The consequences of Alzheimer's disease (AD) (deposition of amyloid plaques and neurofibrillary tangles) are known. The cause of these deposition of proteins is not. Some scientist argue that an increase in oxidative phosphorylation activity and a lack of ability to shift to aerobic glycolysis are the underlying source of these changes. The purpose of this study is to test whether there is a correlation between neuroenergetic levels of aerobic glycolysis/oxidative phosphorylation and risk for Alzheimer's disease. The study will examine these neuroenergetic adaptations in a group of 15 elderly participants (age range: 70-85 y/o) with amnestic mild cognitive impairment (aMCI) and 30 cognitively normal controls (NL). Multimodal (MR/PET) and multinuclear (31P/1H) neuroimaging will allow us to gain access to a uniquely comprehensive and highly consistent view of neuroenergetic adaptations in both the clinical and preclinical stages of Alzheimer's disease.

Eligibility Criteria:
Inclusion Criteria:

* NL Group: Adults (male and female) aged \>70 years in overall excellent health with normal cognition (CDR=0), and at least high school graduate level education.
* aMCI Group: Adults (male and female) aged \>70 years, Clinical Dementia Rating (CDR)= 0.5 - 1 and Mini-Mental State Examination (MMSE): 20-25
* English as first language or demonstrated proficiency in English for non-native speakers

Exclusion Criteria:

* Any tumor, stroke, or trauma that would result in abnormal radiological findings History of bipolar disorder, schizophrenia, intellectual disability or substance abuse MRI scanner contraindications
Optimization of Preventive Effects of Physical Training

Health-promoting effects of physical exercise are well-investigated especially for endurance activities. However, for different individuals, positive effects have different sizes, even non-responders are observed. Other forms of training, such as strength training and interval training, are less well investigated. Therefore, a comparative longitudinal training study is warranted to examine differences of preventive effects (outcome measures: ergometric descriptors of physical performance, established risk factors and prognostic factors for cardiovascular diseases) of continuous endurance training, interval training and strength endurance training.

In a second stage, the observed non-responders will perform a different type of training (cross-over). It is expected, that besides a comparative general efficacy evaluation of the three training types, improved recommendations for optimized individualization of training parameters can be formulated.


Eligibility Criteria:
Inclusion Criteria:

* untrained
* healthy
* non-smoking

Exclusion Criteria:

* Contraindications for physical activity
* BMI \> 30 kg/m2
* resting blood pressure \> 160/100 mmHg
* diabetes
* total cholesterol \> 300 mg/dl
* maximal oxygen uptake \> 50 ml/min/kg for men and \> 45 ml/min/kg for women respectively
* other complaints or diseases that might interfere with exercise training
Effects of Different Ventilatory Strategy on Intraoperative Atelectasis During Bronchoscopy Under General Anesthesia.

This trial compares two different types of ventilation for the prevention of partial or complete collapsed lung (atelectasis) in patients undergoing interventional pulmonology procedures under general anesthesia. Ventilatory strategy to prevent reduce the intra-procedural development of atelectasis during interventional pulmonology procedures under general anesthesia.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients undergoing interventional pulmonology procedures with radial probe endobronchial ultrasound (RP-EBUS) for peripheral lung lesions
* Recent (\< 4 weeks) chest computed tomography (CT) performed prior to the bronchoscopy

Exclusion Criteria:

* Patients with baseline lung consolidation, interstitial changes or lung masses (\> 3 cm in diameter) in dependent areas of the lung (right/left \[R/L\] B6, 9, or 10 bronchial segments) as seen on most recent CT
* History of primary or secondary spontaneous pneumothorax
Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)

This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III and BIOMONITOR IIIm that are discovered or remain even after risk analysis, risk mitigation and successful conformity assessment. Furthermore, this study will also provide additional data as required by regulatory authorities outside of the CE-region.


Eligibility Criteria:
Inclusion Criteria:

* Patient is at high risk of developing a clinically important cardiac arrhythmia; or
* Patient is undergoing investigation for symptoms such as palpitations, pre- syncope or syncope, that are suggestive of an underlying cardiac arrhythmia; or
* Patient is undergoing investigation for the detection of atrial fibrillation following cryptogenic stroke; or
* Patient is planned for AF ablative procedure or has already undergone an AF ablative procedure.
* Patient is able to understand the nature of the study and able to provide written informed consent.
* Patient is willing and able to perform all follow-up visits at the investigational site.
* Patient is willing and able to use the CardioMessenger and accepts the BIOTRONIK Home Monitoring concept.

Exclusion Criteria:

* Patient is implanted with an ICD or pacemaker.
* Patient is pregnant or breast-feeding.
* Patient is less than 18 years old.
* Patient's life-expectancy is less than 12 months.
* Patient is participating in another interventional clinical investigation.
A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

This study is a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial to evaluate the efficacy, safety and immunogenicity of a single dose of Live-Attenuated influenza Vaccine(LAIV) among healthy children and adolescents aged 3-17 years.

This study is a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial to evaluate the efficacy, safety and immunogenicity of a single dose of Live-Attenuated influenza Vaccine(LAIV) among healthy children and adolescents aged 3-17 years old. The subjects will be randomized in a 1:1 ratio of LAIV to placebo. Each subject will be vaccinated with a single dose of LAIV or Placebo. For evaluation of efficacy, subjects meeting the protocol-defined clinical case definition the 14th day post-vaccination will have a nasal swab collected for testing by RT-PCR or virus culture for evidence of influenza virus infection. All adverse events will be collected 30 minutes, 0-30 days after vaccination and all serious adverse events during the entire trial period. Blood samples will be collected from a part of subjects before vaccination and at the 30th day after immunization. Serum samples will be centrifuged for detection of antibodies to H1N1, H3N2, and influenza B.

Eligibility Criteria:
Inclusion Criteria:

1. Healthy children and adolescents aged 3-17 years old.
2. Informed consent obtained and signed by subjects or legal guardians prior to screening. Children or adolescents aged 10-17 yrs need sign informed consent by themselves.
3. Willing to participate for the planned duration of the study, including availability for follow-up.

Exclusion Criteria:

1. Any investigational or unregistered product (drug, vaccine or device) was used within 30 days, or planned to be used during the trial.
2. have been vaccinated with any influenza vaccine within 6 months, or plan to be vaccinated during the trail.
3. Immunosuppressive agents or other immunomodulatory drugs (defined as continuous use for more than 14 days) were used over a 3-month period.
4. Immunoglobulins and / or any blood products were used within 3 months, or planned to be used before blood collection.
5. History of Guillain-Barré syndrome; History of hypersensitivity to any component of the LAIV, including egg or egg products.
6. Severe allergic reactions after vaccination (including anaphylactic shock, allergic laryngeal edema, allergic purpura, local allergic necrosis).
7. Acute diseases , infections or febrile diseases (axillary temperature ≥37.1℃) on the day of vaccination.
8. Obvious coagulation dysfunction or History of anticoagulant therapy
9. Aspirin is being used(Salicylates are a potential risk factor for Reye syndrome)
10. Known or suspected immune deficiency diseases or immunosuppressed
11. Heart disease, respiratory diseases (including severe rhinitis, nasal deformities, polyps, etc.), liver disease, kidney disease, mental disorders, chronic infections etc.
Chatbot Counselling for Smoking Cessation in Youths

The goal of this pilot trial is to develop and examine the trial feasibility and acceptability of a chatbot for smoking cessation in youth smokers. Specific aims include:

1. To assess how many youth smokers accept the invitation to participate in the trial
2. To assess the retention of the participants through 6 months after treatment initiation
3. To assess the acceptability of the chatbot in terms of participants' compliance and usability rating of the chatbot.
4. To estimate the intervention effect on abstinence outcomes
5. To explore the participants' perception and experiences in the chatbot


Eligibility Criteria:
Inclusion Criteria:

1. Hong Kong residents aged 25 years or younger
2. Used a tobacco product in the past 30 days, including cigarettes, electronic cigarettes, heated tobacco products, etc.
3. Able to communicate in Chinese
4. Own a smartphone with internet access

Exclusion Criteria:

1. Diagnosed with a mental disease or on regular psychotropic drugs, or
2. Participating in other ongoing smoking cessation studies.
Soluble Programmed Death 1 (sPD1) is a Diagnostic Biomarker of ILD in Patients With Rheumatoid Arthritis Disease

1. Evaluate the levels of serum (sPD1) in RA patients with ILD and those without.
2. Detect subclinical RA-ILD for early diagnosis and management of this devastating manifestation of RA

Rheumatoid arthritis is a chronic autoimmune disease that is characterized by a systemic inflammatory state that affects joints and other organs .

There are many types of RA-related pulmonary diseases. RA-related pulmonary diseases include airway disease such as bronchiolitis. There are interstitial lung diseases that include non-specific interstitial pneumonitis and usual interstitial pneumonia .

The pathogenesis of RA is multifactorial with contributions from genetic and environmental factors. (CD4+) T-cells is responsible for pro-inflammatory cytokines production and subsequent joint destruction .

The aetiology of RA-ILD may be related to smoking and other factors that activate autoimmunity and the attack of post-transcriptionally modified self-proteins, such as citrullinated peptides. Citrullinated peptide can be produced in the lungs of some patients, causing a pulmonary fibrosis .

Major subtypes of RA-ILD are defined by their histopathological or (HRCT) patterns

. Programmed death-1 belongs to CD28/B7 family and is expressed on the surface of activated T cells, B cells, NK cells, dendritic cells and Treg cells. sPD-1 is the soluble form of PD-1 that is obtained by phosphoric acid hydrolysis of membrane type PD-1 .

Programmed death-1 and its ligands are important negative regulators of the immune system. .

In RA, Persistent synovial T cell activation and inflammation may be reasoned to positive regulators overexpression, aberrant expression of negative regulators or functional antagonism of these molecules by soluble factors .

sPD-1 inhibits the PD-1/PD-L signalling pathway by interacting with PD-Ls and promotes the T cell activation .

Eligibility Criteria:
Inclusion Criteria:

* Adult RA Patients who fulfilled the 2010 ACR/European league against rheumatism (EULAR) criteria for the classification of RA (7).
* Adult RA patients with ILD (Nonspecific idiopathic interstitial pneumonia more than 16 years old).

Exclusion Criteria:

* Patients with other autoimmune diseases (systemic lupus erythematosus, polyarteritis nodosa sarcoidosis, dermatomyositis, scleroderma, spondylarthritis and inflammatory bowel disease).
* RA patients with lung affection other than ILD
* Patients with malignant tumors
* Patients with active infection
* Patients with severe heart, lung, and kidney dysfunction
* Patients with tuberculosis, pulmonary infection, chronic obstructive pulmonary disease, bronchiectasis, lung tumor, and pneumoconiosis disease.
* Uses of drugs (other than RA medication) known to cause ILD such as antimicrobial agents (Sulphonamide), cardiovascular agents (amiodarone) and Bromocriptine.